Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene

Science

Volumn 273, Issue 5283, 1996, Pages 1856-1862

  Dean, Michael ^a   Carrington, Mary ^a   Winkler, Cheryl ^a   Huttley, Gavin A ^a   Smith, Michael W ^a   Allikmets, Rando ^a   Goedert, James J ^a   Buchbinder, Susan P ^a   Vittinghoff, Eric ^a   Gomperts, Edward ^a   Donfield, Sharyne ^a   Vlahov, David ^a   Kaslow, Richard ^a   Saah, Alfred ^a   Rinaldo, Charles ^a   Detels, Roger ^a   O'Brien, Stephen J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; RECEPTOR PROTEIN; T LYMPHOCYTE RECEPTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CHROMOSOME 3P; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GENE DELETION; GENE FREQUENCY; GENE MAPPING; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION SENSITIVITY; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; SEROCONVERSION; STRUCTURAL GENE; SURVIVAL;

EID: 0001633495     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.273.5283.1856     Document Type: Article

References (61)

1. R. May and R. Anderson, Infectious Disease in Humans (Oxford Univ. Press, New York, 1995).
2. S. S. Morse, Ed., Emerging Viruses (Rockefeller Univ. Press, New York, 1993).
3. T. I. A. Sorensen, G. G. Nielsen, P. K. Andersen, T. W. Teasdale, N. Engl. J. Med. 318, 727 (1988).
4. A. G. Motulsky, Human Genetics: Patterns and Approaches (Springer-Verlag, Berlin, 1981).
5. S. Wain-Hobson, Curr. Opin. Genet. Dev. 3, 878 (1993).
6. J. M. Coffin, Science 267, 483 (1995).
7. E. L. Delwart et al., ibid. 262, 1257 (1993).
8. R. A. Kaslow et al., Nature Med. 2, 405 (1996); B. F. Haynes, G. Pantaleo, A. S. Fauci, Science 271, 324 (1996).
9. R. A. Kaslow et al., Nature Med. 2, 405 (1996); B. F. Haynes, G. Pantaleo, A. S. Fauci, Science 271, 324 (1996).
10. W. A. Paxton et al., Nature Med. 2, 412 (1996); R. Detels et al., AIDS 10, 102 (1996).
11. W. A. Paxton et al., Nature Med. 2, 412 (1996); R. Detels et al., AIDS 10, 102 (1996).
12. F. Cocchi et al., Science 270, 1811 (1995); M. Baier, A. Werner, N. Bannert, K. Metzner, R. Kurth, Nature 378, 563 (1995).
13. F. Cocchi et al., Science 270, 1811 (1995); M. Baier, A. Werner, N. Bannert, K. Metzner, R. Kurth, Nature 378, 563 (1995).
14. Y. Feng, C. C. Broder, P. E. Kennedy, E. A. Berger, Science 272, 872 (1996).
15. B. Federsppiel et al., Genomics 16, 707 (1993).
16. H. Herzog, Y. J. Hort, J. Shine, L. A. Selbie, DNA Cell Biol. 12, 465 (1993).
17. H. Nomura, B. W. Nielsen, K. Matsushima, Int. Immunol. 5, 1239 (1993).
18. P. J. Madden et al., Cell 47, 333 (1986).
19. C. Combadiere, S. K. Ahuja, H. L. Tiffany, P. M. Murphy, J. Leukocyte Biol. 60, 147 (1996); M. Samson, O. Labbe, C. Mollereau, G. Vassart, M. Parmentier, Biochemistry 35, 3362 (1996).
20. C. Combadiere, S. K. Ahuja, H. L. Tiffany, P. M. Murphy, J. Leukocyte Biol. 60, 147 (1996); M. Samson, O. Labbe, C. Mollereau, G. Vassart, M. Parmentier, Biochemistry 35, 3362 (1996).
21. T. Dragic et al., Nature 381, 667 (1996).
22. G. Alkhatib et al., Science 272, 1955 (1996).
23. H. Choe et al., Cell 85, 1135 (1996).
24. B. J. Doranz et al., ibid., p. 1149.
25. H. Deng et al., Nature 381, 661 (1996).
26. P. M. Murphy, Annu. Rev. Immunol. 12, 593 (1994).
27. K. Neote, D. DiGregorio, J. Y. Mak, R. Horuk, T. J. Schall, Cell 72, 415 (1993).
28. C. J. Raport et al., J. Leukocyte Biol. 59, 18 (1996).
29. M. A. Walter, D. J. Spillett, P. Thomas, J. Weissenbach, P. Goodfellow, Nature Genet. 7, 22 (1994).
30. M. White, M. Carvalho, D. Derse, S. J. O'Brien, M. Dean, Genomics 12, 301 (1992); M. Ravnik-Glavac, D. Glavac, M. Dean, Hum. Mol. Genet. 3, 801 (1994).
31. M. White, M. Carvalho, D. Derse, S. J. O'Brien, M. Dean, Genomics 12, 301 (1992); M. Ravnik-Glavac, D. Glavac, M. Dean, Hum. Mol. Genet. 3, 801 (1994).
32. M. Orita, Y. Suzuki, T. Sekiua, K. Hayashi, Genomics 5, 874 (1989).
33. M. Samson, Nature 382, 722 (1996).
34. R. Liu et al., Cell 86, 367 (1996).
35. Eight CKR5 variant alleles were found. These include the Δ32 deletion; a variant that occurred as a heterozygote in 15 individuals of ≃600 screened by SSCP; four variants found as heterozygous in single individuals that were HIV-1 infected, but had not progressed to AIDS after 7 to 10 years; and two variants in HIV-1-infected individuals that had not been followed for long term as yet. Preliminary sequence analysis revealed missense alterations in codons for conserved amino acids in three of the variants.
36. M. W. Hilgartner et al., Am. J. Pediatr. Hematol. Oncol. 15, 208 (1993).
37. J. J. Goedert et al., N. Engl. J. Med. 321, 1141 (1989).
38. J. J. Goedert et al., Am. J. Epidemiol. 121, 629 (1985).
39. R. A. Kaslow et al., ibid. 126, 310 (1987); J. Phair et al., J. AIDS 5, 490 (1992); R. Detels et al., ibid. 7, 1263 (1996).
40. R. A. Kaslow et al., ibid. 126, 310 (1987); J. Phair et al., J. AIDS 5, 490 (1992); R. Detels et al., ibid. 7, 1263 (1996).
41. R. A. Kaslow et al., ibid. 126, 310 (1987); J. Phair et al., J. AIDS 5, 490 (1992); R. Detels et al., ibid. 7, 1263 (1996).
42. S. P. Buchbinder, AIDS 8, 1123 (1994).
43. D. Vlahov et al., NIDA Research Monograph Series 103 (Public Health Service, Alcohol and Drug Abuse Administration, Washington, DC, 1991).
44. M. Dean et al., Am. J. Hum. Genet. 55, 788 (1994).
45. J. C. Stephens, D. Briscoe, S. J. O'Brien, ibid., p. 809.
46. 2 values [R. R. Sokal and F. J. Rohlf, Biometry (Freeman, New York, 1981)]. For all significant values, a Fisher's exact test gave similar results.
47. 2 values [R. R. Sokal and F. J. Rohlf, Biometry (Freeman, New York, 1981)]. For all significant values, a Fisher's exact test gave similar results.
48. The ALIVE cohort is composed of African American intravenous drug users and includes 496 homozygous (+/+) and 9 heterozygous (+/Δ32) individuals. With so few individuals with the CKR5Δ32 allele, the ALIVE cohort was not included in subsequent computations. Although behavioral variables are probably more important, the relatively low CKR5Δ32 allele frequency in African Americans may contribute to a higher rate of infection in this ethnic group among intravenous drug users [D. Vlahov et al., Am. J. Epidemiol. 132, 847 (1990)].
49. M. Dean et al., data not shown.
50. A significant reduction in heterozygotes (+/Δ32) was observed among HIV-1-seronegative individuals. This result warrants further study.
51. With the Bonferroni correction for multiple tests (four tests), the individual homosexual cohorts are not significant. When the two homosexual cohorts are combined, although they have different definitions of rapid progression, the result is significant (P = 0.005), even after corrections for multiple tests [B. S. Weir, Genetic Data Analysis II (Sinauer, Sunderland, MA, 1996)].
52. Centers for Disease Control, Morb. Mortal. Wkly. Rep. 36 (suppl. 1) (14 August 1987).
53. _, ibid. 41 (18 December 1992). This publication contains a revised classification system for HIV infection and an expanded surveillance case definition for AIDS among adolescents and adults.
54. J. W. Mellors et al., Science 272, 1167 (1996).
55. T. R. O'Brien et a/., J. Am. Med. Assoc. 276, 105 (1996).
56. R. L. Cann, M. Stoneking, A. C. Wilson, Nature 325, 31 (1987).
57. R. Chakraborty and P. E. Smouse, Proc. Natl. Acad. Sci. U.S.A. 85, 3071 (1988).
58. S. J. O'Brien, Curr. Biol. 1, 209 (1991).
59. Radiation hybrid DNAs, obtained from Research Genetics, were amplified for 20 min in a 10-μl PCR reaction with the following primers: for CKR5, primers CCK5F2 (5′-GGTGGAACAAGATGGATTAT-3′) and CCK5R2 (5′-CATGTGCACAACTCTGACTG-3′); for fusin, primers FUSF1 (5′-TGTACGTGTGTCTAGGCAGG-3′) and FUSR1 (5′-TGTAGGTGCTGAAATCAACCC-3′); and for CKR1, primers CKRF1 (5′-TCCCACTGCCAAGAACTTG-3′) and CKRR1 (5′-TTCCCCAGGATTCCAAGAG-3′). Samples were amplified with 5 units of Taq Gold (Stratagene) in the supplier's buffer in a Cetus 9600 PCR machine with a 58°C annealing temperature and loaded onto a 1.5% agarose gel. Scores for 90 radiation hybrids were recorded, and the results were analyzed by the Whitehead Mapping Server (http://www-genome! wi.mit.edu/cgi-bin/contig/rhmapper.pl) to determine significant linkages onto the framework map. RH typing data is available on request at e-mail address dean@ncifcrf.gov.
60. HGDS investigators: A. Willoughby, National Institute of Child Health and Human Development, Bethesda, MD; W. Kesell, Bureau of Maternal and Child Health and Resources Development, Bethesda, MD; D. Mann, Univ. of Maryland; W. Pequegnat, National Institute of Mental Health, Bethesda, MD. The following individuals are the center directors, study coordinators, or committee chairs of the HGDS study: Childrens Hospital, Los Angeles - F. Kaufman, M. Nelson, S. Pearson; The New York Hospital-Comell Medical Ctr. - M. Hilgartner, S. Cunningham-Rundles, J. Gertner, I. Goldberg; Univ. of Texas Medical Sch., Houston - W. K. Hoots, K. Loveland, M. Cantini, G. Casterline; NIH, National Institute of Child Health and Human Development, Bethesda, MD - A. Willoughby; New England Research Institutes, Incorporated (Data Coordinating Center), Watertown - S. Donfield, M. A. Maeder; Baylor College of Medicine - C. Contant Jr.; Univ. of Iowa Hospitals and Clinics, Iowa City - C. T. Kisker, J. Stehbens, J. Bale, S. O'Conner; Tulane Univ. - P. Sirois; Children's Hospital of Oklahoma, Oklahoma City - C, Sexauer, H. Huszti, S. Hawk, F. Kiplinger; Mount Sinai Medical Ctr., New York City - S. Arkin, A. Forster; Univ. of Nebraska Medical Ctr. - S. Swindells, S. Richard; Univ. of Texas Health Science Ctr., San Antonio - J. Mangos, A. Scott, R. Davis; Children's Hospital of Michigan, Detroit - J. Lusher, I. Warner, K. Baird-Cox; Milton S. Hershey Medical Ctr., Hershey, PA - M. E. Eyster, E. Pattishall, D. Ungar, S. Neagley; Univ. of Indiana, James Whitcomb Riley Hospital for Children - A. Shapiro, S. Hatcher; Univ. of California-San Diego Medical Ctr. - G. Davignon, P. Rabwin: Kansas City Sch. of Medicine, Children's Mercy Hospital - B. Wicklund, A. Mehrhof. MHCS investigators: M. E. Eyster, Milton S. Hershey Medical Ctr., Hershey; M. Hilgartner, Cornell Medical Ctr.; A. Cohen, Children's Hospital of Philadelphia; B. Konkle, Tnomas Jefferson Univ. Hospital; G. Bray, Children's Hospital National Medical Ctr., Washington, DC; L. Aledort, Mount Sinai Medical Ctr., New York City; C. Kessler, George Washington Univ. Medical Ctr.; C. Leissinger, Tulane Medical Sch.; G. White, Univ. of North Carolina; M. Lederman, Case Western Reserve Medical School, Cleveland; P. Blatt, Christiana Hospital; M. Manco-Johnson, Univ. of Colorado.
61. We are indebted to the children, adolescents, adults, and parents who have volunteered to participate in this study, and to the members of the Hemophilia Treatment Centers. We thank D. Lomb, S. Edelstein, M. Malasky, T. Kissner, D. Marti, B. Gerrard, A. Hutchinson, M. Weedon, X. Wu, P. Lloyd, E. Wendel, M. McNally, R. Boaze, L. Kenefic, M. Konsavich, C. Stewart, and S. Cevario for technical assistance, and B. Weir, M. Clegg, R. Adamson, and R. Gallo for helpful discussions. Computing resources were provided by the Frederick Biomedical Supercomputing Center. Supported by the Bureau of Maternal and Child Health and Resources Development (MCJ-060570), the National Institute of Child Health and Human Development (NO1-HD-4-3200), the Centers for Disease Control and Prevention, the National Institute of Mental Health, and the National Institute of Drug Abuse (DA04334). Additional support has been provided by grants from the National Center for Research Resources (General Clinical Research Centers) of NIH to the New York Hospital-Cornell Medical Center Clinical Research Center (MO1-RR06020), the Mount Sinai General Clinical Research Center, New York (MO1-RR00071), the University of Iowa Clinical Research Center (MO1-RR00059), and the University of Texas Health Science Center, Houston (MO1-RR02558). The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.